– USA, MA – Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi therapeutic platform, today announced the appointment of Robert Bitterman as interim Executive Chairman of the Board of Directors.
Mr. Bitterman has served as a director on the Company’s Board since 2012 and brings 25 years of executive leadership experience in the pharmaceutical and biologic life science industry coupled with prior experience in senior financial and investor relations roles.
The Company is also pleased to announce the appointment of Robert Ferrara as Lead Independent Director. Mr. Ferrara currently serves as the Chairman of the Audit Committee of the Board. \
Mr. Ferrara has served as a director on the Company’s Board since 2019. He has held numerous senior executive-level financial positions in both domestic and international public and private companies in a variety of industries, including pharmaceuticals and life sciences. Mr. Ferrara is a Certified Public Accountant and earned a BS degree in accounting from Lehigh University.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi therapeutic platform. The Company’s efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. The Company’s goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients with a powerful new treatment option that goes beyond current treatment modalities.
For more information: https://phiopharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.